CYTOKIND INC

CYTOKIND INC specializes in clinical research and development focused on novel phototherapeutic interventions for infectious and inflammatory conditions, with demonstrated expertise in non-broadband ultraviolet B (NB-UVB) therapy validation. The company conducts end-to-end clinical validation studies designed to support regulatory submissions to the U.S. Food and Drug Administration, particularly for repurposing established physical therapy modalities into new therapeutic indications. Their technical capabilities include protocol design, patient recruitment strategy, data acquisition from clinical settings, and regulatory documentation preparation aligned with FDA guidance for new drug indications. This places them at the intersection of clinical dermatology, immunomodulatory therapy, and translational research, with a distinct focus on non-pharmacological interventions for viral pathologies such as COVID-19. The contractor has delivered services exclusively for the Department of Health and Human Services, specifically supporting initiatives under agencies engaged in public health innovation and therapeutic development. Their engagement reflects a targeted, mission-driven relationship centered on advancing non-pharmaceutical treatment pathways within the HHS ecosystem, particularly through the National Institutes of Health or its operational arms focused on infectious disease response. CYTOKIND INC operates under NAICS 541715, which encompasses applied research in life sciences excluding biotechnology and nanotechnology. In practice, this means they conduct hypothesis-driven, human-subject research aimed at validating physical or environmental therapeutic modalities, positioning them as a niche provider in the clinical validation space rather than drug discovery or device manufacturing. Their market focus is on evidence generation for underutilized physical therapies with scalable, low-cost potential for public health deployment. As a small business structured as a 2L entity based in Exeter, New Hampshire, CYTOKIND INC maintains a lean, research-focused operational model. The company currently holds no federal certifications, relying instead on scientific rigor and regulatory pathway expertise to compete in the federal research contracting landscape. Their geographic presence is localized but strategically aligned with academic and clinical research hubs in the Northeast.